Opendata, web and dolomites


Development of a Next-Generation, Dual-Target Rabies/Flavivirus Infectious DNA (iDNA) Vaccine

Total Cost €


EC-Contrib. €






 RABYD-VAX project word cloud

Explore the words cloud of the RABYD-VAX project. It provides you a very rough idea of what is the project "RABYD-VAX" about.

yellow    efficient    vaccines    children    danger    excellent    routine    paediatric    protection    hamsters    protective       yfv    likewise    proprietary    die    idna    japanese    express    protects    disease    platform    needle    plasmid    compliance    fever    despite    micro    p01a    combine    lethal    versatile    launches    demonstrated    rabies    stability    unvaccinated    cold    rate    employ    fatality    vaccination    vector    doses    uncontrollable    free    deadliest    existence    zika    commercial    annually    yf    10    dual    small    life    models    animal    chimeric    thermostable    medical    immunity    administered    half    rhesus    benefits    99    clinical    chain    infectious    vaccine    naked    virus    safe    prequalification    58    30    dose    sufficient    customize    regulatory    attenuated    live    tech    mice    yearly    outbreaks    ease    earth    cheap    injection    prophylactic    encephalitis    dna    macaques    antigens    induction    candidates    people    thermo   

Project "RABYD-VAX" data sheet

The following table provides information about the project.


Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website
 Total cost 4˙113˙385 €
 EC max contribution 4˙113˙385 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 1˙818˙113.00
4    SCIENSANO BE (ELSENE) participant 649˙705.00


 Project objective

Rabies is the deadliest disease on earth (99.9% fatality rate). Annually, ~58.000 people die from rabies, more than half of them are children. Many remain unvaccinated because of the high costs and the need for a cold-chain. Likewise, despite the existence of an excellent yellow fever (YF) vaccine, yearly ~30.000 people die of YF. The 80-year old low-tech production process does not allow to produce sufficient doses. There is now a real danger that major YF-outbreaks become uncontrollable. We aim at developing an efficient, safe, cheap, thermostable and easy-to-produce vaccine that can be needle-free administered, that protects against both rabies and YF, and that can be implemented in routine prophylactic paediatric vaccination. For this, we will employ our (P01a) proprietary infectious DNA (iDNA) vaccine technology. Simple, even needle-free injection of a low dose (1-10µg) of this easy-to-produce naked plasmid in mice and hamsters launches the YF vaccine virus and protects hamsters as efficiently as the commercial vaccine against lethal YF challenge. The iDNA YF vaccine will be used as vector to express relevant protective rabies antigens. Dual protection of such chimeric iDNA rabies/YF vaccine will be demonstrated against lethal rabies and YFV challenge in small animal models. Likewise, chimeric rabies/Japanese encephalitis and rabies/Zika virus iDNA vaccine candidates will be generated using this versatile platform. Next, induction of protective immunity will be demonstrated in rhesus macaques. The iDNA vaccines combine the benefits of both the YF live-attenuated vaccine (highly efficient life-long induction of immunity) and the thermo-stability, ease-of-production and the potential to customize (in response to emerging medical needs) of “classical” DNA vaccines. A path towards advanced pre-clinical and clinical development of such novel vaccines will be developed in compliance with European regulatory and WHO prequalification requirements.


List of deliverables.
Dissemination and Communication Measures Documents, reports 2019-05-31 16:34:02

Take a look to the deliverables list in detail:  detailed list of RABYD-VAX deliverables.


year authors and title journal last update
List of publications.
2019 Rebecca Shipley, Edward Wright, David Selden, Guanghui Wu, James Aegerter, Anthony R Fooks, Ashley C Banyard
Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU
published pages: 31, ISSN: 2414-6366, DOI: 10.3390/tropicalmed4010031
Tropical Medicine and Infectious Disease 4/1 2020-03-11
2018 Dieudonné B. Kum, Niraj Mishra, Robbert Boudewijns, Ivan Gladwyn-Ng, Christian Alfano, Ji Ma, Michael A. Schmid, Rafael E. Marques, Dominique Schols, Suzanne Kaptein, Laurent Nguyen, Johan Neyts, Kai Dallmeier
A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice
published pages: , ISSN: 2059-0105, DOI: 10.1038/s41541-018-0092-2
npj Vaccines 3/1 2020-03-11
2018 Ashley C. Banyard, David Selden, Guanghui Wu, Leigh Thorne, Daisy Jennings, Denise Marston, Stefan Finke, Conrad M. Freuling, Thomas Müller, Juan E. Echevarría, Anthony R. Fooks
Isolation, antigenicity and immunogenicity of Lleida bat lyssavirus
published pages: 1590-1599, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001068
Journal of General Virology 99/12 2020-03-11
2019 Dieudonné Buh Kum, Niraj Mishra, Bram Vrancken, Hendrik Jan Thibaut, Annelies Wilder-Smith, Philippe Lemey, Johan Neyts, Kai Dallmeier
Limited evolution of the yellow fever virus 17d in a mouse infection model
published pages: 1734-1746, ISSN: 2222-1751, DOI: 10.1080/22221751.2019.1694394
Emerging Microbes & Infections 8/1 2020-03-11
2019 Samuel P. Smith, Guanghui Wu, Anthony R. Fooks, Julian Ma, Ashley C. Banyard
Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS
published pages: 1171-1186, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001269
Journal of General Virology 100/8 2020-03-11
2018 Jennifer Evans, Guanghui Wu, David Selden, Hubert Buczkowski, Leigh Thorne, Anthony Fooks, Ashley Banyard
Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses
published pages: 130, ISSN: 1999-4915, DOI: 10.3390/v10030130
Viruses 10/3 2019-06-11
2018 E. Kip, J. Staal, L. Verstrepen, H. G. Tima, S. Terryn, M. Romano, K. Lemeire, V. Suin, A. Hamouda, M. Kalai, R. Beyaert, S. Van Gucht
MALT1 Controls Attenuated Rabies Virus by Inducing Early Inflammation and T Cell Activation in the Brain
published pages: , ISSN: 0022-538X, DOI: 10.1128/JVI.02029-17
Journal of Virology 92/8 2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABYD-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RABYD-VAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  


Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Read More